Scalper1 News
Health care giants Johnson & Johnson (JNJ) and Bristol-Myers Squibb (BMY) both got upgraded to buy Tuesday, as analysts saw bright futures for their drugs despite the current market pounding. UBS analyst Marc Goodman raised his price target on Bristol-Myers to 75 from 65 and upgraded the stock to buy from neutral. He lifted his 2020 sales estimate on the recently launched cancer drug Opdivo to $10 billion from $8 billion, based on results from a Scalper1 News
Scalper1 News